Publications by authors named "M R Capeding"
Article Synopsis
- The study assessed the safety and effectiveness of a new COVID-19 booster vaccine (PIKA-adjuvanted recombinant) for adults who have already received two doses of an inactivated vaccine.
- Participants were divided into two groups: one received the PIKA vaccine, while the other got an inactivated vaccine, with their safety monitored and immune response measured through antibody levels over time.
- Results showed that the PIKA vaccine significantly increased neutralizing antibodies against both the Omicron variant and the original SARS-CoV-2 virus shortly after vaccination, although there was no long-term difference in antibody levels between the two vaccines after 90 days.
A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies.
Vaccine
September 2024
Background: SYN023 is an anti-rabies monoclonal antibody mixture administered as part of post-exposure prophylaxis regimens. The rabies virus neutralizing antibody (RVNA) concentration generally accepted as an adequate immune response to vaccination is ≥ 0.5 IU/mL.
View Article and Find Full Text PDFThe 6th Asia Dengue Summit (ADS) themed "Road Map to Zero Dengue Death" was held in Thailand from 15th-16th June 2023. The summit was hosted by Tropical Medicine Cluster, Chulalongkorn University, Bangkok, Thailand in conjunction with Queen Saovabha Memorial Institute, The Thai Red Cross Society; Faculty of Tropical Medicine, Mahidol University; and the Ministry of Public Health. The 6th ADS was convened by Asia Dengue Voice and Action (ADVA); Global Dengue and Aedes Transmitted Diseases Consortium (GDAC); Southeast Asian Ministers of Education Tropical Medicine and Public Health Network (SEAMEO TROPMED); Fondation Mérieux (FMx) and the International Society for Neglected Tropical Diseases (ISNTD).
View Article and Find Full Text PDFIntroduction: subspecies infantis () may play a key role in infant gut development. This trial evaluated safety, tolerability, and efficacy of LMG11588 supplementation.
Methods: This randomized, placebo-controlled, double-blind study conducted in the Philippines included healthy breastfed and/or formula-fed infants (14-21 days old) randomized for 8 weeks to a control group (CG; = 77), or any of two experimental groups (EGs): low (Lo-EG; 1*10 CFU/day; = 75) or high dose (Hi-EG; 1.
Korean manufacturers have developed a new varicella vaccine, NBP608. This phase 3, randomized, double-blind, multicenter study aimed to compare the immunogenicity and safety of NBP608 in healthy children to those of Varivax (control). Children aged 12 months to 12 years were randomized in a ratio of 1:1 to receive either NBP608 or the control vaccine.
View Article and Find Full Text PDF